Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
5,400
Employees5,400
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
5,400
Employees5,400

PODD Key Statistics

Market cap
10.33B
Market cap10.33B
Price-Earnings ratio
34.72
Price-Earnings ratio34.72
Dividend yield
Dividend yield
Average volume
1.57M
Average volume1.57M
High today
High today
Low today
Low today
Open price
$150.03
Open price$150.03
Volume
0.00
Volume0.00
52 Week high
$354.88
52 Week high$354.88
52 Week low
$140.63
52 Week low$140.63

Stock Snapshot

As of today, Insulet(PODD) shares are valued at $149.19. The company's market cap stands at 10.33B, with a P/E ratio of 34.72.

On 2026-06-12, Insulet(PODD) shares started trading at $150.03, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 1.57M.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $140.63.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $140.63.

PODD News

MarketWatch 15h
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch

...

Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
TipRanks 18h
Insulet price target lowered to $219 from $250 at Truist

Truist lowered the firm’s price target on Insulet (PODD) to $219 from $250 and keeps a Buy rating on the shares after hosting an NDR meeting with Insulet’s mana...

Simply Wall St 2d
Does Insulet’s Omnipod 6 Data Reframe Its Type 2 Diabetes Automation Ambitions?

Insulet recently used the American Diabetes Association’s 86th Scientific Sessions to unveil new clinical data on its investigational Omnipod 6 and fully closed...

Does Insulet’s Omnipod 6 Data Reframe Its Type 2 Diabetes Automation Ambitions?

Analyst ratings

89%

of 27 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

More PODD News

Nasdaq 4d
Monday 6/8 Insider Buying Report: PODD, ADC

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably...

Monday 6/8 Insider Buying Report: PODD, ADC
TipRanks 5d
Insulet announces new results on tubeless AID systems

Insulet (PODD) announced new clinical results highlighting the “next breakthroughs” in tubeless Automated Insulin Delivery, AID, systems. The data and growing b...

Simply Wall St 5d
Assessing Insulet Valuation After New Omnipod 6 And Closed Loop Diabetes Data

Insulet (PODD) just released new clinical data on its future Omnipod 6 and fully closed loop systems, showing improved glucose control across type 1 and type 2...

Assessing Insulet Valuation After New Omnipod 6 And Closed Loop Diabetes Data

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.